P
Pauline Funchain
Researcher at Cleveland Clinic
Publications - 99
Citations - 1914
Pauline Funchain is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 17, co-authored 68 publications receiving 872 citations. Previous affiliations of Pauline Funchain include Cleveland Clinic Lerner Research Institute & Case Western Reserve University.
Papers
More filters
Journal ArticleDOI
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.
Bryan J. Schneider,Jarushka Naidoo,Bianca Santomasso,Christina Lacchetti,Sherry Adkins,Milan J. Anadkat,Michael B. Atkins,Kelly J. Brassil,Jeffrey M. Caterino,Ian Chau,Marianne Davies,M. S. Ernstoff,Leslie A. Fecher,Monalisa Ghosh,Ishmael Jaiyesimi,Jennifer S. Mammen,Aung Naing,Loretta J. Nastoupil,Tanyanika Phillips,Laura Diane Porter,Cristina A. Reichner,Carole Seigel,Jung-Min Song,Alexander I. Spira,Maria E. Suarez-Almazor,Umang Swami,John A. Thompson,Praveen Vikas,Yinghong Wang,Jeffrey S. Weber,Pauline Funchain,Kathryn Bollin +31 more
TL;DR: In this article, the recommended management of immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitor (ICP) was discussed. But, the authors did not provide guidance on recommended management.
Journal ArticleDOI
Systemic Therapy for Melanoma: ASCO Guideline.
Rahul Seth,Hans Messersmith,Varinder Kaur,John M. Kirkwood,Ragini R. Kudchadkar,Jennifer L. McQuade,Anthony F. Provenzano,Umang Swami,Jeffrey S. Weber,Krishna C Alluri,Sanjiv S. Agarwala,Paolo A. Ascierto,Michael B. Atkins,Nancy B. Davis,Marc S. Ernstoff,Mark B. Faries,Jason S. Gold,Samantha Guild,David E. Gyorki,Nikhil I. Khushalani,Michael O. Meyers,Caroline Robert,Mario Santinami,Amikar Sehdev,Vernon K. Sondak,Gilliosa Spurrier,Katy K. Tsai,Alexander C.J. van Akkooi,Pauline Funchain +28 more
TL;DR: A systematic review of the literature found that patients with mucosal melanoma may be offered the same therapies recommended for cutaneous melanoma, while no recommendation could be made for or against specific therapy for uveal melanoma.
Journal ArticleDOI
Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis
Hamzah Abu-Sbeih,Faisal Ali,Abdul Rafeh Naqash,Dwight H. Owen,Sandipkumar Patel,Gregory A. Otterson,Kari Kendra,Biagio Ricciuti,Rita Chiari,Andrea De Giglio,Joseph Sleiman,Pauline Funchain,Beatriz Wills,Jiajia Zhang,Jarushka Naidoo,Jessica Philpott,Jianjun Gao,Sumit K. Subudhi,Yinghong Wang +18 more
TL;DR: One third of patients who resumed ICI treatment after IMDC experienced recurrent IMDC, and recurrence of IMDC was less frequent after resuming of anti–PD-1/L1 than after resumption of anti-CTLA-4.
Journal ArticleDOI
Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of anti-PD-1 Therapies in Metastatic Melanoma
Douglas B. Johnson,Jennifer Bordeaux,Ju Young Kim,Christine Vaupel,David L. Rimm,Thai H. Ho,Richard W. Joseph,Adil Daud,Robert M. Conry,Elizabeth M. Gaughan,Leonel Hernandez-Aya,Anastasios Dimou,Pauline Funchain,James W. Smithy,John S. Witte,Svetlana B. McKee,Jennifer S. Ko,John Wrangle,Bashar Dabbas,Shabnam Tangri,Jelveh Lameh,Jeff Hall,Joseph Markowitz,Justin M. Balko,Naveen Dakappagari +24 more
TL;DR: Quantitative spatial profiling of key tumor-immune suppression pathways by novel digital pathology algorithms could help more reliably select melanoma patients for PD-1 monotherapy.
Journal ArticleDOI
Prospective Clinical Study of Precision Oncology in Solid Tumors.
Davendra Sohal,Brian I. Rini,Alok A. Khorana,Robert Dreicer,Jame Abraham,Gary W. Procop,Yogen Saunthararajah,Nathan A. Pennell,James P. Stevenson,R. Pelley,Bassam Estfan,Dale R. Shepard,Pauline Funchain,Paul Elson,David J. Adelstein,Brian J. Bolwell +15 more
TL;DR: A prospective study in 250 patients with select solid tumors at the Cleveland Clinic, finding that lack of clinical trial access and clinical deterioration were the most common reasons for nonrecommendation/nonreceipt of genomics-driven therapy.